Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness

High Altitude Medicine and Biology

Volumn 9, Issue 1, 2008, Pages 15-23

  Kayser, Bengt ^a   Hulsebosch, Ronald ^b   Bosch, Frank ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b De Reisdokter   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Altitude; Cyclooxygenase; Epidemiology

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID DERIVATIVE; CARBASALATE CALCIUM; DEXAMETHASONE; IBUPROFEN; OXYGEN; PARACETAMOL; PLACEBO;

ADULT; ALTITUDE DISEASE; ARTICLE; BRAIN EDEMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACETAZOLAMIDE; ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; ASPIRIN; CARBONIC ANHYDRASE INHIBITORS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MOUNTAINEERING; NEPAL; PULMONARY EDEMA; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UREA;

EID: 40549122976     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2007.1037     Document Type: Article

References (20)

1. Bailey D.M., Roukens R., Knauth M., Kallenberg K., Christ S., Mohr A., Genius J., Storch-Hagenlocher B., Meisel F., Mceneny J., Young I.S., Steiner T., Hess K., and Bartsch P. (2006). Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache. J. Cereb. Blood Flow Metab. 26:99-111.
2. Barry P.W., and Pollard A.J. (2003). Altitude illness. BMJ. 326:915-919.
3. Basnyat B., Gertsch J.H., Holck P.S., Johnson E.W., Luks A.M., Donham B.P., Fleischman R.J., Gowder D.W., Hawksworth J.S., Jensen B.T., Kleiman R.J., Loveridge A.H., Lundeen E.B., Newman S.L., Noboa J.A., Miegs D.P., O'Beirne K.A., Philpot K.B., Schultz M.N., Valente M.C., Wiebers M.R., and Swenson E.R. (2006). Acetazolamide 125 mg bd is not significantly different from 375 mg bd in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt. Med. Biol. 7:17-27.
4. Basnyat B., and Murdoch D.R. (2003). High-altitude illness. Lancet. 361:1967-1974.
5. Burtscher M., Likar R., Nachbauer W., and Philadelphy M. (1998). Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ. 316:1057-1058.
6. Burtscher M., Likar R., Nachbauer W., Philadelphy M., Puhringer R., and Lammle T. (2001). Effects of aspirin during exercise on the incidence of high-altitude headache: a randomized, double-blind, placebo-controlled trial. Headache. 41:542-545.
7. Carlsten C., Swenson E.R., and Ruoss S. (2004). A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt. Med. Biol. 5:33-39.
8. Diener H.C., and Ringleb P. (2002). Antithrombotic secondary prevention after stroke. Curr. Treatment Options Cardiovasc. Med. 4:429-440.
9. Dumont L., Lysakowski C., Tramer M.R., and Kayser B. (2005). Controversies in altitude medicine. Travel Med. Infect. Dis. 3:183-188.
10. Dumont L., Mardirosoff C., and Tramer M.R. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 321:267-272.
11. Hackett P.H., and Roach R.C. (2001). High-altitude illness. N. Engl. J. Med. 345:107-114.
12. Kallenberg K., Bailey D.M., Christ S., Mohr A., Roukens R., Menold E., Steiner T., Bartsch P., and Knauth M. (2007). Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J. Cereb. Blood Flow Metab. 27:1064-1071.
13. Leaf D.E., and Goldfarb D.S. (2007). Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 102:1313-1322.
14. Murray F.E., Hudson N., Atherton J.C., Cole A.T., Scheck F., and Hawkey C.J. (1996). Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut. 38:11-14.
15. Richalet J.P., Hornych A., Rathat C., Aumont J., Larmignat P., and Remy P. (1991). Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxia. Respir. Physiol. 85:205-215.
16. Roach R.C, Bärtsch P., Oelz O., and Hackett P.H. (1993). The Lake Louise Acute Mountain Sickness Scoring System. In: Hypoxia and Molecular Medicine. J.R. Sutton, C.S. Houston, and G. Coates, eds. Queen City Press, Burlington, VT; pp. 272-274.
17. Roach R.C., and Hackett P.H. (2001). Frontiers of hypoxia research: acute mountain sickness. J. Exp. Biol. 204:3161-3170.
18. Schilling L., and Wahl M. (1999). Mediators of cerebral edema. In: Hypoxia: Into the Next Millennium. R.C. Roach, P.D. Wagner, and P.H. Hackett, eds. Plenum/Kluwer Academic Publishing, New York; pp. 123-141.
19. Schoonman G.G., Sandor P.S., Nirkko A.C., Lange T., Jaermann T., Dydak U., Kremer C., Ferrari M.D., Boesiger P., and Baumgartner R.W. (2008). Hypoxia-induced acute mountain sickness is associated with intracellular cerebral edema: a 3 t magnetic resonance imaging study. J. Cereb. Blood Flow Metab. 28:198-206.
20. Wu K.K. (2003). Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin. Vasc. Med. 3:107-112.